To evaluate the association between UGT1A1 gene promoter polymorphism and hyperbilirubinemia in Korean chronic myeloid leukemia patients treated with Nilotinib and Radotinib as a frontline therapy

Trial Profile

To evaluate the association between UGT1A1 gene promoter polymorphism and hyperbilirubinemia in Korean chronic myeloid leukemia patients treated with Nilotinib and Radotinib as a frontline therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs Nilotinib (Primary) ; Radotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Aug 2015 New trial record
    • 14 Jun 2015 Results (n=94) presented at the 20th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top